The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Clinical Trial Authorisation to a potential preventative therapy for Cytokine Release Syndrome (CRS).  The TOPICAL trial will investigate Poolbeg Pharma’s therapy, POLB 001, in approximately 30 relapsed/refractory multiple myeloma patients receiving the approved bispecific antibody teclistamab.  Previous research showed POLB 001, if approved, could help patients manage CRS, […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!